Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1977;4(Suppl 2):215S–220S. doi: 10.1111/j.1365-2125.1977.tb05755.x

Controlled randomized group comparison of nomifensine and imipramine in depressive illness

A Forrest, A Hewett, P Nicholson
PMCID: PMC1429136  PMID: 334226

Abstract

1 Nomifensine, an isoquinoline dopaminergic agonist, was investigated in a randomized double-blind group comparison with imipramine, in 40 out-patients with depression.

2 Assessments were made at weekly intervals for 4 weeks using the Hamilton Depression Scale and the Beck Depression Inventory. Blood, kidney and liver function were also monitored weekly.

3 Nomifensine was shown to be at least as effective as imipramine in relieving depression and to relieve the anxiety component of the disease significantly more rapidly. Neither drug produced serious unwanted effects.

Full text

PDF
215S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexanderson B., Evans D. A., Sjöqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J. 1969 Dec 27;4(5686):764–768. doi: 10.1136/bmj.4.5686.764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Angst J. Erfolg und Misserfolg der psychopharmakologischen Therapie am Beispiel der Depression. Hippokrates. 1965 Dec 31;36(24):946–951. [PubMed] [Google Scholar]
  3. Angst J., Koukkou M., Bleuler-Herzog M., Martens H. Ergebnisse eines offenen und eines Doppelblindversuches von Nomifensin im Vergleich zu Imipramin. Arch Psychiatr Nervenkr (1970) 1974;219(3):265–276. doi: 10.1007/BF00342052. [DOI] [PubMed] [Google Scholar]
  4. BECK A. T., WARD C. H., MENDELSON M., MOCK J., ERBAUGH J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561–571. doi: 10.1001/archpsyc.1961.01710120031004. [DOI] [PubMed] [Google Scholar]
  5. Baltzer V., Delini-Stula A., Bein H. J. Ricerche farmacologiche sulla maprotilina nuova sostanza ad azione antidepressiva. Boll Chim Farm. 1973 Sep;112(9):601–619. [PubMed] [Google Scholar]
  6. Costall B., Kelly D. M., Naylor R. J. Nomifensine: a potent dopaminergic agonist of antiparkinson potential. Psychopharmacologia. 1975;41(2):153–164. doi: 10.1007/BF00421073. [DOI] [PubMed] [Google Scholar]
  7. Costall B., Naylor R. J. Actions of dopaminergic agonists on motor function. Adv Neurol. 1975;9:285–297. [PubMed] [Google Scholar]
  8. Coyle J. T., Snyder S. H. Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science. 1969 Nov 14;166(3907):899–901. doi: 10.1126/science.166.3907.899. [DOI] [PubMed] [Google Scholar]
  9. Gerhards H. J., Carenzi A., Costa E. Effect of nomifensine on motor activity, dopamine turnover rate and cyclic 3',5;-adenosine monophosphate concentrations of rat striatum. Naunyn Schmiedebergs Arch Pharmacol. 1974;286(1):49–63. doi: 10.1007/BF00499104. [DOI] [PubMed] [Google Scholar]
  10. HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56–62. doi: 10.1136/jnnp.23.1.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hamilton M. General problems of psychiatric rating scales (especially for depression). Mod Probl Pharmacopsychiatry. 1974;7(0):125–138. doi: 10.1159/000395072. [DOI] [PubMed] [Google Scholar]
  12. Hoffmann I., Ehrhart G., Schmitt K. 8-Amino-4-phenyl-1,2,3,4-tetrahydroisochinoline, eine neue Gruppe antidepressiver Psychopharmaka. Arzneimittelforschung. 1971 Jul;21(7):1045–1045. [PubMed] [Google Scholar]
  13. Horn A. S., Coyle J. T., Snyder S. H. Catecholamine uptake by synaptosomes from rat brain. Structure-activity relationships of drugs with differential effects on dopamine and norepinephrine neurons. Mol Pharmacol. 1971 Jan;7(1):66–80. [PubMed] [Google Scholar]
  14. Hunt P., Kannengiesser M., Raynaud J. Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum. J Pharm Pharmacol. 1974 May;26(5):370–371. doi: 10.1111/j.2042-7158.1974.tb09294.x. [DOI] [PubMed] [Google Scholar]
  15. Leyburn P. A critical look at antidepressant drug trials. Lancet. 1967 Nov 25;2(7526):1135–1138. doi: 10.1016/s0140-6736(67)90635-6. [DOI] [PubMed] [Google Scholar]
  16. Mallion K. B., Todd A. H., Turner R. W., Bainbridge J. G., Greenwood D. T., Madinaveitia J., Somerville A. R., Whittle B. A. 2-(2-ethoxyphenoxymethyl)tetrahydro-1,4-oxazine hydrochloride, a potential psychotropic agent. Nature. 1972 Jul 21;238(5360):157–158. doi: 10.1038/238157a0. [DOI] [PubMed] [Google Scholar]
  17. Schacht U., Heptner W. Effect of nomifensine (HOE 984), a new antidepressant, on uptake of noradrenaline and serotonin and on release of noradrenaline in rat brain synaptosomes. Biochem Pharmacol. 1974 Dec 15;23(24):3413–3422. doi: 10.1016/0006-2952(74)90344-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES